Union Health Minister Dr. Harsh Vardhan
– Photo: ANI
Hear the news
Sources said on Wednesday that the vaccine will be much cheaper than the vaccines currently being provided by two foreign companies. The drug regulator of India allowed the vaccine ‘Pneumococcal Polysaccharide Conjugate’ to be launched in July itself after reviewing the first, second and third phase data of clinical trials of vaccines received from a Pune-based institute.
The Ministry of Health had earlier reported that the vaccine enhances immunity to the disease caused by ‘Streptococcus pneumoniae’ in infants. The Serum Institute has conducted clinical trials of the first, second and third stages of the vaccine in India and the African nation of Gambia. Official sources said, “This is the first indigenously developed vaccine in the field of pneumonia.”
Sources said the vaccine would be more affordable than Pfizer’s NYSE PFE and GlaxoSmithKline’s LSE GSK. In a letter to the Health Minister, Prakash Kumar Singh, Under-Director of Government and Regulatory Affairs at the Serum Institute said, “It has always been our endeavor to fulfill the Prime Minister’s dream under the Vocal for Local and Make in India for the world.”
He wrote, ‘Moving towards the call of Prime Minister (Narendra Modi) for a self-reliant India, we have taken a historic mile by developing India’s first global-class pneumonia vaccine and taking Indian license for it during the lockdown of the Kovid-19 epidemic. Has installed the stone. ‘ According to UNICEF figures, pneumonia kills more than one lakh children in the age group of zero to five every year in India.